Arcadia Biosciences, Inc. (RKDA) News

Arcadia Biosciences, Inc. (RKDA): $0.89

-0.03 (-3.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RKDA to Watchlist
Sign Up

Industry: Agriculture


Ranked

of 33

in industry

Filter RKDA News Items

RKDA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RKDA News From Around the Web

Below are the latest news stories about Arcadia Biosciences Inc that investors may wish to consider to help them evaluate RKDA as an investment opportunity.

Arcadia Biosciences hires brand marketing veteran Jacot as CEO

Arcadia Biosciences Inc. has hired a food and brand marketing veteran as its new CEO. Stan Jacot, previously president of Jane’s Dough Foods in the Columbus, Ohio area, became CEO on Wednesday. Jacot has had senior marketing and operations roles at Mission Foods in Texas, Borden Dairy Co., ConAgra Brands Inc. (NYSE: CAG) and Kellogg Co. (NYSE: K).

Yahoo | February 3, 2022

Arcadia Biosciences appoints CEO

Arcadia Biosciences (RKDA) appointed consumer veteran Stan Jacot as CEO effective Feb. 2

Seeking Alpha | February 2, 2022

Arcadia Biosciences (RKDA) Names Stan Jacot as CEO

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, has appointed veteran consumer goods leader Stan Jacot as chief executive officer, effective today.

Yahoo | February 2, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | January 5, 2022

H.C. Wainwright Thinks Arcadia Biosciences’ Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Arcadia Biosciences (RKDA – Research Report), with a price target of $6.00. The company's shares closed last Friday at $1.04, close to its 52-week low of $0.99. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $5.25.

Howard Kim on TipRanks | January 3, 2022

Arcadia Biosciences board chairman stepping in as interim CEO

The chairman of the board of Arcadia Biosciences Inc. will take over as interim CEO as the board completes a search for a permanent top executive.

Yahoo | December 20, 2021

Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the

Yahoo | December 20, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | December 10, 2021

Arcadia Biosciences - An Update

No summary available.

Seeking Alpha | November 29, 2021

Arcadia Biosciences (RKDA) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | November 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.395 seconds.